TNDM · Tandem Diabetes Care Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $247.22M | - | $249.25M | $240.68M | $234.42M | - | $243.97M | $221.91M | $191.67M | - |
| Cost of Revenue | $110.43M | - | $114.96M | $114.82M | $116.02M | - | $119.32M | $109.12M | $97.00M | - |
| Gross Profit | $136.79M | - | $134.29M | $125.86M | $118.41M | - | $124.65M | $112.79M | $94.67M | - |
| R&D | $46.03M | - | $48.72M | $48.12M | $50.22M | - | $51.11M | $49.33M | $46.24M | - |
| SG&A | $108.19M | - | $108.44M | $109.60M | $113.85M | - | $99.64M | $94.24M | $90.11M | - |
| Total Operating Expenses | $154.22M | - | $157.16M | $177.66M | $239.28M | - | $150.75M | $143.57M | $136.35M | - |
| D&A | $4.50M | - | - | - | $4.31M | - | - | - | $4.04M | - |
| Operating Income | ($17.43M) | - | ($22.86M) | ($51.81M) | ($120.88M) | - | ($26.09M) | ($30.77M) | ($41.68M) | - |
| Interest Expense | $2.20M | - | $2.06M | $1.91M | $1.90M | - | $4.84M | $1.79M | - | - |
| Income Tax | $516.0K | - | ($3.98M) | ($5.32M) | $8.47M | - | $637.0K | $1.07M | $3.19M | - |
| Net Income | ($20.39M) | - | ($21.16M) | ($52.40M) | ($130.56M) | - | ($23.25M) | ($30.81M) | ($42.72M) | - |
| EPS - Basic | ($0.30) | - | ($0.31) | ($0.78) | ($1.97) | - | ($0.35) | ($0.47) | ($0.65) | - |
| EPS - Diluted | ($0.30) | - | ($0.31) | ($0.78) | ($1.97) | - | ($0.35) | ($0.47) | ($0.65) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $179.32M | $90.63M | $91.95M | $64.11M | $53.57M | $69.23M | $49.04M | $47.70M | $58.98M | $58.87M |
| Accounts Receivable | $140.67M | $165.49M | $125.94M | $128.44M | $126.56M | $114.58M | $107.19M | $98.12M | $92.97M | $105.56M |
| Inventory | $126.40M | $128.77M | $137.28M | $142.57M | $141.16M | $149.61M | $152.44M | $161.66M | $153.89M | $157.94M |
| Accounts Payable | $59.86M | $47.07M | $47.48M | $55.84M | $59.80M | $44.73M | $48.75M | $47.78M | $48.14M | $49.59M |
| Current Assets | $887.10M | $618.14M | $616.94M | $614.82M | $663.43M | $724.49M | $752.83M | $733.39M | $735.19M | $747.99M |
| Total Assets | $1.15B | $881.11M | $874.65M | $875.74M | $922.14M | $967.66M | $957.73M | $937.50M | $941.04M | $952.66M |
| Current Liabilities | $247.96M | $242.72M | $252.54M | $251.69M | $288.18M | $247.05M | $259.28M | $240.61M | $192.97M | $195.26M |
| Long-term Debt | $601.77M | $310.04M | $309.59M | $309.15M | $308.70M | $308.27M | $307.83M | $285.04M | - | - |
| Total Liabilities | $1.02B | $725.94M | $741.69M | $742.45M | $766.85M | $704.56M | $720.02M | $703.63M | $697.98M | $639.03M |
| Stockholders' Equity | $132.40M | $155.17M | $132.97M | $133.28M | $155.29M | $263.10M | $237.71M | $233.88M | $243.06M | $313.63M |
| Retained Earnings | ($1.27B) | ($1.25B) | ($1.25B) | ($1.23B) | ($1.18B) | ($1.05B) | ($1.05B) | ($1.03B) | ($994.51M) | ($951.80M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $11.05M | - | - | - | ($18.28M) | - | - | - | ($8.00M) | - |
| Investing Cash Flow | ($195.45M) | - | - | - | $9.19M | - | - | - | ($5.06M) | - |
| Financing Cash Flow | $274.16M | - | - | - | ($4.69M) | - | - | - | $13.59M | - |
| CapEx | $6.27M | - | - | - | $2.96M | - | - | - | $4.46M | - |
| Free Cash Flow | $4.79M | - | - | - | ($21.24M) | - | - | - | ($12.45M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 55.3% | - | 53.9% | 52.3% | 50.5% | - | 51.1% | 50.8% | 49.4% | - |
| Operating margin | -7.1% | - | -9.2% | -21.5% | -51.6% | - | -10.7% | -13.9% | -21.7% | - |
| EBITDA margin | -5.2% | - | - | - | -49.7% | - | - | - | -19.6% | - |
| Net margin | -8.2% | - | -8.5% | -21.8% | -55.7% | - | -9.5% | -13.9% | -22.3% | - |
| Free cash flow margin | 1.9% | - | - | - | -9.1% | - | - | - | -6.5% | - |
| FCF / Net income | -0.23 | - | - | - | 0.16 | - | - | - | 0.29 | - |
| R&D / Revenue | 18.6% | - | 19.5% | 20.0% | 21.4% | - | 20.9% | 22.2% | 24.1% | - |
| SG&A / Revenue | 43.8% | - | 43.5% | 45.5% | 48.6% | - | 40.8% | 42.5% | 47.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -1.8% | - | -2.4% | -6.0% | -14.2% | - | -2.4% | -3.3% | -4.5% | - |
| Return on equity | -15.4% | - | -15.9% | -39.3% | -84.1% | - | -9.8% | -13.2% | -17.6% | - |
| Return on invested capital | -1.9% | - | -4.1% | -9.3% | -20.6% | - | -3.8% | -4.7% | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.58 | 2.55 | 2.44 | 2.44 | 2.30 | 2.93 | 2.90 | 3.05 | 3.81 | 3.83 |
| Quick ratio | 3.07 | 2.02 | 1.90 | 1.88 | 1.81 | 2.33 | 2.32 | 2.38 | 3.01 | 3.02 |
| Cash ratio | 0.72 | 0.37 | 0.36 | 0.25 | 0.19 | 0.28 | 0.19 | 0.20 | 0.31 | 0.30 |
| Leverage | ||||||||||
| Debt / Equity | 4.54 | 2.00 | 2.33 | 2.32 | 1.99 | 1.17 | 1.29 | 1.22 | - | - |
| Debt / Assets | 0.52 | 0.35 | 0.35 | 0.35 | 0.33 | 0.32 | 0.32 | 0.30 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -7.9x | - | -11.1x | -27.2x | -63.7x | - | -5.4x | -17.2x | - | - |
| Equity multiplier | 8.71 | 5.68 | 6.58 | 6.57 | 5.94 | 3.68 | 4.03 | 4.01 | 3.87 | 3.04 |
| Liabilities / Assets | 0.89 | 0.82 | 0.85 | 0.85 | 0.83 | 0.73 | 0.75 | 0.75 | 0.74 | 0.67 |
| Efficiency | ||||||||||
| Asset turnover | 0.21 | - | 0.28 | 0.27 | 0.25 | - | 0.25 | 0.24 | 0.20 | - |
| Inventory turnover | 0.87 | - | 0.84 | 0.81 | 0.82 | - | 0.78 | 0.67 | 0.63 | - |
| Days sales outstanding | 208d | - | 184d | 195d | 197d | - | 160d | 161d | 177d | - |
| Days inventory outstanding | 418d | - | 436d | 453d | 444d | - | 466d | 541d | 579d | - |
| Days payable outstanding | 198d | - | 151d | 177d | 188d | - | 149d | 160d | 181d | - |
| Cash conversion cycle | 428d | - | 470d | 471d | 453d | - | 478d | 542d | 575d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 9.9x | - | 6.2x | 9.4x | 8.2x | - | 11.7x | 11.2x | 9.5x | - |
| P / S | 5.3x | - | 3.3x | 5.2x | 5.4x | - | 11.4x | 11.8x | 12.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 5.5% | - | 2.2% | 8.5% | 22.3% | - | 31.4% | 13.3% | 13.2% | - |
| Revenue CAGR (3y) | 13.4% | - | 6.8% | 6.3% | 10.0% | - | 10.7% | 8.8% | 10.8% | - |
| Revenue CAGR (5y) | 11.9% | - | 15.1% | 17.1% | - | - | 20.8% | 18.9% | 14.4% | - |
| Gross profit growth (YoY) | 15.5% | - | 7.7% | 11.6% | 25.1% | - | 38.9% | 10.9% | 14.2% | - |
| Operating income growth (YoY) | 85.6% | - | 12.4% | -68.4% | -190.0% | - | 17.3% | 20.7% | 67.4% | - |
| Net income growth (YoY) | 84.4% | - | 9.0% | -70.1% | -205.6% | - | 29.5% | 13.9% | 65.5% | - |
| EPS growth (YoY) | 84.8% | - | 11.4% | -66.0% | -203.1% | - | 31.4% | 14.5% | 66.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -70.6% | - | - | - | 54.1% | - |
| FCF CAGR (5y) | -28.2% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -14.7% | -41.0% | -44.1% | -43.0% | -36.1% | -16.1% | -24.3% | -29.0% | -28.2% | -28.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$1.01B totalSupplies And Other$550.60M · 54.3%
Pump$464.14M · 45.7%
Geographic
$1.01B totalUS$706.94M · 69.7%
Non Us$307.80M · 30.3%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing TANDEM DIABETES CARE INC against the 5 most active filers in the same SIC group.